Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SHE:002693)
China · Delayed Price · Currency is CNY 9.54
-0.44 (-4.41%)
Aug 21, 2026, 9:45 AM CST
SHE:002693 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,139 | 2,886 | 7,601 | 3,129 | 3,015 | 1,945 | |
Market Cap Growth | 19.52% | -62.03% | 142.94% | 3.77% | 55.05% | 10.89% |
Enterprise Value | 4,363 | 3,136 | 7,793 | 3,255 | 3,130 | 2,127 |
Last Close Price | 9.98 | 6.96 | 18.33 | 7.51 | 7.27 | 4.72 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 116.88 | 151.56 | - | - | 334.55 | - |
Forward PE | - | 18.69 | 18.69 | 18.69 | 18.69 | 18.69 |
PS Ratio | 14.34 | 10.43 | 43.63 | 13.26 | 10.97 | 6.07 |
PB Ratio | 9.86 | 6.86 | 18.47 | 6.04 | 5.19 | 3.43 |
P/TBV Ratio | 13.16 | 9.38 | 22.66 | 7.47 | 6.83 | 4.83 |
P/FCF Ratio | 105.41 | 163.27 | - | - | - | - |
P/OCF Ratio | 48.13 | 47.36 | - | 268.82 | 119.56 | 82.56 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 15.12 | 11.33 | 44.73 | 13.80 | 11.39 | 6.64 |
EV/EBITDA Ratio | 51.68 | 44.81 | - | 205.51 | 235.43 | 451.32 |
EV/EBIT Ratio | 136.31 | 180.72 | - | - | - | - |
EV/FCF Ratio | 111.12 | 177.38 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.70 | 0.67 | 0.67 | 0.36 | 0.38 | 0.31 |
Debt / EBITDA Ratio | 3.49 | 4.01 | - | 11.75 | 16.80 | 37.71 |
Debt / FCF Ratio | 7.50 | 15.88 | - | - | - | - |
Net Debt / Equity Ratio | 0.53 | 0.53 | 0.56 | 0.30 | 0.13 | 0.18 |
Net Debt / EBITDA Ratio | 2.61 | 3.17 | -12.63 | 9.73 | 5.82 | 21.36 |
Net Debt / FCF Ratio | 5.61 | 12.54 | -3.52 | -4.10 | -9.96 | -12.45 |
Asset Turnover | 0.37 | 0.34 | 0.22 | 0.28 | 0.31 | 0.36 |
Inventory Turnover | 1.79 | 1.81 | 1.09 | 1.18 | 1.57 | 1.62 |
Quick Ratio | 0.42 | 0.45 | 0.41 | 0.43 | 0.58 | 1.01 |
Current Ratio | 0.66 | 0.67 | 0.88 | 0.97 | 0.79 | 1.53 |
Return on Equity (ROE) | 5.33% | 2.14% | -22.87% | -13.10% | -1.48% | -7.00% |
Return on Assets (ROA) | 2.54% | 1.35% | -5.65% | -2.69% | -3.13% | -3.52% |
Return on Invested Capital (ROIC) | 4.99% | 2.70% | -10.92% | -5.54% | -6.67% | -7.15% |
Return on Capital Employed (ROCE) | 6.20% | 3.30% | -11.80% | -5.60% | -7.50% | -6.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.79% | 0.66% | -1.03% | -1.62% | 0.30% | -1.04% |
FCF Yield | 0.95% | 0.61% | -0.86% | -1.20% | -0.26% | -0.42% |
Payout Ratio | 22.20% | 38.16% | - | - | 123.52% | - |
Buyback Yield / Dilution | 7.58% | 7.59% | 2.53% | 6.16% | -10.85% | 0.91% |